Drug Profile
OQR 300
Alternative Names: OQR-300Latest Information Update: 08 Sep 2023
Price :
$50
*
At a glance
- Originator OncoQR
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 08 Sep 2023 Preclinical development in Cancer is ongoing in Austria (OncoQR pipeline, September 2023)
- 28 Jan 2020 No recent reports of development identified for preclinical development in Cancer in Austria
- 31 Dec 2015 Preclinical trials in Cancer in Austria (unspecified route)